CARBIDOPA-LEVODOPA

Generic	Brand	HICL	GCN	Exception/Other
CARBIDOPA/LEVODOPA	DUOPA		37829	ROUTE = Percutaneous endoscopic gastrostomy with jejunal tube (PEG-J)

GUIDELINES FOR USE

1. Does the patient have a diagnosis of Parkinson's disease?

   If yes, **approve for 12 months by GPID for 100mL per day.**
   If no, do not approve.
   DENIAL TEXT: Our guideline for **CARBIDOPA-LEVODOPA** requires a diagnosis of advanced Parkinson's disease.

RATIONALE
Promote appropriate utilization of Duopa based on FDA approved indication.

Duopa is the first agent to provide continuous treatment via the enteral route for motor fluctuations in patients with Parkinson’s disease. It provides patients with the same active ingredients as orally-administered carbidopa and levodopa immediate release, but is delivered in a suspension that bypasses the stomach and goes directly into the small intestine via a tube placed by a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J).

FDA APPROVED INDICATION
Duopa is indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.

DOSAGE
Duopa is administered over a 16-hour infusion period. The daily dose is determined by individualized patient titration and composed of a morning dose, a continuous dose, and extra doses. The maximum recommended daily dose of Duopa is 2000mg of the levodopa component. At the end of the daily 16-hour infusion, patients will disconnect with pump from the PEG-J and take their nighttime dose of oral immediate release carbidopa/levodopa tablets.

Duopa is administered into the jejunum through a percutaneous endoscopic gastrostomy with jejunal tube (PEG-J) with the CADD®-Legacy 1400 portable infusion pump. A Duopa cassette should be taken out of the refrigerator and out of the carton 20 minutes prior to use so that it can be administered at room temperature. The cassettes are for single-use only.

CONTINUED ON NEXT PAGE

CARBIDOPA-LEVODOPA

REFERENCES

- Duopa [Prescribing Information]. North Chicago, IL: Abbvie, Inc. January 2015.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A
Commercial Effective: 07/01/15
Created: 05/15
Client Approval: 05/15
P&T Approval: 05/15